Modeling the impact of RV144-like vaccines on HIV transmission

Vaccine

Volumn 29, Issue 36, 2011, Pages

  Hankins, Catherine A ^a   Glasser, John W ^b   Chen, Robert T ^b  

^a UNAIDS   (Switzerland)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALVAC; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; UNCLASSIFIED DRUG;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CD4 LYMPHOCYTE COUNT; CONSULTATION; DRUG EFFECT; DRUG EFFICACY; HIGH RISK POPULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MATHEMATICAL MODEL; NOTE; PRIORITY JOURNAL; THAILAND; VIRUS LOAD; VIRUS TRANSMISSION;

ADULT; AIDS VACCINES; CLINICAL TRIALS AS TOPIC; FEMALE; HIV; HIV INFECTIONS; HUMANS; IMMUNIZATION, SECONDARY; MALE; MODELS, THEORETICAL;

EID: 80051468872     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.07.001     Document Type: Note

References (20)

1. Council of the Global HIV Vaccine Enterprise The 2010 scientific strategic plan of the Global HIV Vaccine Enterprise. Nat Med 2010, 16:981-989.
2. rgp120 HIV Vaccine Study Group Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J Infect Dis 2005, 191:654-665.
3. Pitisuttithum P., Gilbert P., Gurwith M., Heyward W., Martin M., van Griensven F., et al. Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J Infect Dis 2006, 194:1661-1671.
4. Buchbinder S.P., Mehrotra D.V., Duerr A., Fitzgerald D.W., Mogg R., Li D., et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 2008, 372:1881-1893.
5. Fauci A.S., Johnston M.I., Dieffenbach C.W., Burton D.R., Hammer S.M., Hoxie J.A., et al. HIV vaccine research: the way forward. Science 2008, 321:530-532.
6. Rerks-Ngarm S., Pitisuttithum P., Nitayaphan S., Kaewkungwal J., Chiu J., Paris R., et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009, 361:2209-2220.
7. Hankins C, Macklin R, Michael N, Stablein D. Recommendations for the future utility of the RV144 vaccines to the Thai Ministry of Health, Report on a meeting in Bangkok, Thailand, 16-18 March 2010. Retrieved from: http://www.vaccineenterprise.org/sites/default/files/RV144_March16-18_Meeting_Report_FINAL.pdf.
8. Shattock R.J., Warren M., McCormack S., Hankins C.A. Turning the Tide Against HIV. Science 2011, 333:42-43.
9. Gilbert P.B., Berger J.O., Stablein D., Becker S., Essex M., Hammer S.M., et al. Statistical interpretation of the RV144 HIV vaccine efficacy trial in Thailand: a case study for statistical issues in efficacy trials. J Infect Dis 2011, 203:969-975.
10. Orenstein W.A., Bernier R.H., Dondero T.J., Hinman A.R., Marks J.S., Bart K.J., et al. Field evaluation of vaccine efficacy. Bull World Health Organ 1985, 63:1055-1068.
11. Smith P.G., Rodrigues L.C., Fine P.E.M. Assessment of the protective efficacy of vaccines against common diseases using case-control and cohort studies. Int J Epidemiol 1984, 13:87-93.
12. Breslow N.E. Covariance analysis of censored survival data. Biometrics 1974, 30:89-99.
13. Hankins C.A., de Zalduondo B.O. Combination prevention: a deeper understanding of effective HIV prevention. AIDS 2010, (October (Suppl. 4)):S70-S80.
14. UNAIDS/WHO/SACEMA Expert Group on Modeling the Impact and Cost of Male Circumcision for HIV Prevention Male circumcision for HIV prevention in high HIV prevalence settings: what can mathematical modeling contribute to informed decision making?. PLoS Med 2009, 6(9):e1000109. 10.1371/journal.pmed.1000109.
15. Bollinger L., Plosky W.D., Stover J. Male circumcision: Decision Makers' Program Planning Tool, Calculating the Costs and Impacts of a Male Circumcision Program 2009, Futures Group, Health Policy Initiative, Task Order 1, Washington, DC.
16. Alistar S.S., Brandeau M.L. Decision making for HIV prevention and treatment scale up: bridging the gap between theory and practice. Med Decis Making 2010, December 29 [Epub ahead of print].
17. Walker L.M., Phoga S.K., Chan-Hui P.-Y., Wagner D., Phung P., Goss J.L., et al. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 2009, Published online September 3. 10.1126/science.1178746.
18. Wu X., Yang Z.Y., Li Y., Hogerkorp C.M., Schief W.R., Seaman M.S., et al. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 2010, 329:856-861.
19. Bomsel M., Tudor D., Drillet A.S., Alfsen A., Ganor Y., Roger M.G., et al. Immunization with HIV-1 gp41 subunit virosomes induces mucosal antibodies protecting nonhuman primates against vaginal SHIV challenges. Immunity 2011, 34:269-280.
20. Hansen S.G., Ford J.C., Lewis M.S., Ventura A.B., Hughes C.M., Coyne-Johnson L., et al. Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine. Nature 2011, 473:523-527.